- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07939061
Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder (URIS-1)
Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial
This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.
Przegląd badań
Status
Szczegółowy opis
Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.
Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.
The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Zuzana Jiraskova, MD, FEAPU
- Numer telefonu: +420 224 967 859
- E-mail: zuzana.jiraskova@vfn.cz
Kopia zapasowa kontaktu do badania
- Nazwa: Petra Novakova, MD
- Numer telefonu: +420 224 967 859
- E-mail: petra.novakova@vfn.cz
Lokalizacje studiów
-
-
-
Prague, Czechy, 128 08
- Rekrutacyjny
- General University Hospital
-
Kontakt:
- Zuzana Jiraskova, MD, FEAPU
- Numer telefonu: +420 224 967 859
- E-mail: zuzana.jiraskova@vfn.cz
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Children aged 7 to 12 years, boys and girls
- Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
- At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
- No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
- Ability and willingness of the child and the parent to follow the protocol; signed informed consent
Exclusion Criteria:
- Severe daytime incontinence (complete wetting in more than 50% of episodes)
- Anticholinergic treatment for overactive bladder in the last 3 months
- Neurogenic lower urinary tract dysfunction
- Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
- Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
- Local lesions of the lower limbs (skin disease, osteosynthesis material)
- Peripheral neuropathy of the lower limbs
- Presence of an electronic implant in the body (e.g., a neurostimulator)
- Functional constipation during the previous 3 months (Rome III-IV criteria)
- Symptomatic urinary tract infection
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Active stimulation
Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks. |
Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal. |
|
Pozorny komparator: Sham stimulation
Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks. |
Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of clinical responders at the end of treatment
Ramy czasowe: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)
|
A clinical responder is a child who meets either or both of the following criteria at the end of treatment:
|
Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in the number of daytime incontinence episodes per 24 hours
Ramy czasowe: Baseline, Week 6, Week 12
|
Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in the severity of daytime incontinence episodes
Ramy czasowe: Baseline, Week 6, Week 12
|
Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in the number of wet days
Ramy czasowe: Baseline, Week 6, Week 12
|
Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in micturition frequency and functional bladder capacity
Ramy czasowe: Baseline, Week 6, Week 12
|
Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in DVISS total score (parent-rated)
Ramy czasowe: Baseline, Week 6, Week 12
|
Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms. |
Baseline, Week 6, Week 12
|
|
Change in Bower PIN-Q total score (child-rated)
Ramy czasowe: Baseline, Week 6, Week 12
|
Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline. |
Baseline, Week 6, Week 12
|
|
PGI-I score rated by the child and by the parent
Ramy czasowe: Week 6, Week 12
|
Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse). |
Week 6, Week 12
|
|
CGI-I score rated by the unblinded investigator
Ramy czasowe: Week 6, Week 12
|
Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse). |
Week 6, Week 12
|
|
Number, type and severity of treatment-related adverse events
Ramy czasowe: From the first stimulation to Week 12
|
Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit. |
From the first stimulation to Week 12
|
|
Adherence to treatment
Ramy czasowe: Week 12
|
Proportion of participants who attend at least 80% of the 12 planned stimulation sessions. |
Week 12
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Zuzana Jiraskova, MD, FEAPU, General University Hospital, Prague
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Zaburzenia psychiczne
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Zaburzenia oddawania moczu
- Objawy dolnych dróg moczowych
- Manifestacje urologiczne
- Objawy behawioralne
- Zaburzenia eliminacji
- Choroby Pęcherza Moczowego
- Stany patologiczne, oznaki i objawy
- Zachowanie
- Objawy i symptomy
- Moczenie mimowolne
- Pęcherz moczowy, nadczynność
- Enureza dzienna
Inne numery identyfikacyjne badania
- Uris_01_2026
- 000058 (Inny identyfikator: ISZP)
- sukls114680/2026 (Inny identyfikator: State Institute for Drug Control (SUKL))
- sukl222573/2026 (Inny identyfikator: State Institute for Drug Control (SUKL))
- 376/26 A, IB, D, PS (Inny identyfikator: Ethics Committee, General University Hospital in Prague)
- 443/26 A, IB (Inny identyfikator: Ethics Committee, General University Hospital in Prague)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .